Faes Farma (BME:FAE) Stock Price Reflects Q3 Earnings Margin Strain

Faes Farma closed today at €4.83 after Q3 2026 earnings, with the share price reflecting a market that is still trying to make sense of a solid but pressured quarter. The headline is clear. Net income from ongoing operations came in at €17.25 million on €172.08 million of revenue, and the squeeze on profitability remains the central story.

Short term traders will focus on the softer quarterly profit picture. Long term holders are more likely to weigh that margin pressure against a 10.9% trailing net profit margin, the current 18.7x P/E and a discounted cash flow value that is currently above where Faes Farma trades today.

Love Faes Farma's solid 10.9% trailing net margin but uneasy about the visible squeeze on recent profitability and the 18.7x P/E? Take a look at our curated list of quality companies with stronger earnings resilience in the list of solid balance sheet and fundamentals stocks (202 results).

Q3 2026 Faes Farma Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): €172.08 million vs €146.61 million (higher quarterly revenue level year on year)
• Net Income from Ongoing Operations (Q3 2026 vs Q3 2025): €17.25 million vs €21.23 million (lower quarterly profit level year on year)
• Basic EPS (Q3 2026 vs Q2 2026): €0.055 vs €0.084 (quarter on quarter EPS decline)
• Trailing 12-Month Net Profit Margin (Q3 2026 vs Q3 2025): 10.9% vs 18.4% (margin compression over the past year)

Earnings tell you how Faes Farma performed this quarter, but investors who care about what they are paying for the business usually focus on the cash coming in and out of the operation over time.

On Faes Farma's cash flows alone, the stock could be a hefty 38% undervalued.

Faes Farma’s growth engines under the microscope

Faes Farma’s upbeat story hinges on new platforms doing more of the heavy lifting as older products mature.

"The integration of SIFI and Edol is adding ophthalmology as a new therapeutic platform, which expands Faes Farma's addressable market and can support a broader revenue base and scale benefits for EBITDA and earnings."

Ophthalmology now represents 16% of group turnover, which confirms that SIFI and Edol are scaling into a meaningful pillar. The latest quarter shows higher group revenue alongside a weaker net income line and a 10.9% trailing margin, so breadth is arriving but the hoped for efficiency and earnings leverage are still only partially visible.

Faes Farma’s key risks confronting reality

The bear story focuses on whether integration costs and product pressure keep Faes Farma’s profitability pinned down.

"The integration of SIFI and Edol and the move to the new Derio plant are still in progress and already driving higher depreciation, amortisation, personnel and restructuring costs."

Q3 underlines that concern. Revenue reached €172.08 million yet net income from ongoing operations was €17.25 million and trailing margin sits at 10.9%, below last year’s 18.4%. Margin compression alongside higher depreciation and personnel expense indicates that integration and footprint changes are still depressing earnings quality, even as the top line benefits from the broader portfolio.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Hunt For Mispriced Cash Generators

Faes Farma’s mixed quarter shows how earnings stories and share prices do not always line up cleanly. The real opportunity is finding stocks that could be undervalued before the market reassesses them.

• Company 1 - 39% below our estimate - directs growing electrification, decarbonization and data demand into ownership of critical infrastructure assets.
• Company 2 - 50% below our estimate - develops an aviation aftermarket platform by adding engine repair capacity and strengthening parts distribution relationships.
• Company 3 - 24% below our estimate - supplies grid diagnostics and RF testing systems for utility upgrades, reliability work and aerospace verification.

Three companies from the same screener. Open the full list of 201 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com